Barely Significant
← all excerpts

Phase 2b Trial of the PDE10A Inhibitor MK-8189 in People With an Acute Episode of Schizophrenia.

J Clin Psychopharmacol · 2026 · PMC13105519 · PMID 41724750

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

nominally significantP <0.001actually significant
The differences between MK-8189 16 and 24 mg versus risperidone (−8.5 kg, and −7.3 kg, respectively) were nominally significant ( P <0.001).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.